Leadership changes at Navidea

• Navidea Biopharmaceuticals (NYSE:NAVB) appoints Michael Goldberg, M.D. interim CEO replacing Dr. Mark Pykett who will step down to head up Manocept technology development. A search for a permanent CEO with global sales experience is underway.
• The firm is working to establish new sources of non-dilutive funding such as collaborations as it cuts spending to a level that can be offset by Lymphoseek revenue.